27
Jan
2010
Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Oncology, X - Vaccines
Bellicum Pharmaceuticals (Houston, TX) a clinical-stage biopharmaceutical company focused on immune-modulating therapeutic vaccines for prostate cancer, closed a $4.5M Series A financing. Particiapnts include the Texas Emerging Technology Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb